JPRN-UMIN000017050已完成2 期
First-Line Afatinib in Patients Aged 75 or Older With Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation -Multicenter study on the Pharmacokinetics and pharmacogenetics of Afatinib- - First-Line Afatinib in Patients Aged 75 or Older
Hokkaido University Hospital, First department of medicine0 个研究点目标入组 35 人开始时间: 2015年4月10日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Concomitant treatment with other anticancer agent, radiotherapy, or immunotherapy. 2)Preexisting interstitial lung disease of chest CT 3)HBs antigen positive 4)HBs or HBc antibody positive, and HBV-DNA positive 5)EGFR minor mutation or exon 20 T790M 6)Active double cancer 7)Digestive disease influencing absorption of afatinib 8)Oral feeding difficulty 9)Patients whose attending doctor consider as inappropriate for this study
研究者
相似试验
已完成
2 期
First-line afatinib in patients aged 75 or older with advanced non-squamous non-small cell lung cancer harboring EGFR mutations; non-randomized phase II trialpatients aged 75 or older with advanced non-squamous non-small cell lung cancer harboring EGFR mutationsJPRN-UMIN000017877on Profit Organization North East Japan Study Group38
招募中
2 期
Phase 2 study of afatinib in advanced elderly NSCLC patients harboring sensitive EGFR mutatioJPRN-UMIN000014820Gunma University Graduate School of Medicine40
招募中
2 期
Phase II study of low-dose afatinib for elderly patients with non-small cell lung cancer harboring EGFR mutation (based on TDM)JPRN-UMIN000022252Shizuoka Cancer Center25
已完成
2 期
First-line afatinib for elderly patientspatients aged 75 or older with advanced non-squamous non-small cell lung cancer harboring EGFR mutatJPRN-jRCTs031180136Gemma Akihiko38
已完成
1 期
Dose-escalation Study of Afatinib in Elderly Patients with EGFR mutation for Non-Small Cell Lung Canceron-small cell lung cancerJPRN-UMIN000016441Hirosaki University Graduate School of Medicine18